Trials / No Longer Available
No Longer AvailableNCT00624741
Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pergolide | Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. |
Timeline
- First posted
- 2008-02-27
- Last updated
- 2012-06-22
Source: ClinicalTrials.gov record NCT00624741. Inclusion in this directory is not an endorsement.